Japanese Pharmaceutical Marketing Company So-net M3 Estimates Double-digit Growth
This article was originally published in PharmAsia News
Executive Summary
Japanese pharmaceutical information provider So-net M3 reported April 23 that the company's net profit increased by 20 percent to ¥2.3 billion ($23.7 million), the company also increased dividends by ¥300 to ¥3000. For fiscal year 2009, M3 estimated another double-digit growth rate of 14 percent in net profit to ¥2.7 billion. So-net M3 has expanded marketing support service for Japanese domestic pharmaceutical companies; the company also is growing overseas businesses, mainly targeting the U.S. market. (Click here for more - Japanese language
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.